WaterPods developed a proprietary water treatment technology for the $2.6 billion US market for residential recreational water care. WaterPods crosses the traditional barriers between chemical and device manufacturers to create a disruptive solution to a problem experienced by over 12 million home owners who maintain their own pools and hot tubs: sustaining clear, pure, fresh water.
Thinoptics is developing revolutionary eye wear that fits conveniently on the back of a smartphone to address reading glasses and sunglasses.
AirXpanders is developing a next generation tissue expansion platform for use in reconstructive surgery and burn treatment. AirXpanders was co-founded by Dr. Dan Jacobs, a leading reconstructive surgeon at Kaiser Permanente in the San Francisco Bay Area and Barry Cheskin, a seasoned medical device entrepreneur. Dr. Jacobs brought to Shalon Ventures his desire for a more effective and more automated tissue expander. Barry Cheskin brought expertise in fundraising and operations for medical device start-ups. Shalon Ventures provided the seed funding, technical and business know-how to address this unmet medical need.
Renew Medical is focused on the design and development of innovative treatments in women’s health. The company has recently developed a device that is indicated for the management of Accidental Bowel Leakage (ABL) due to bowel incontinence. New single-use Renew Inserts are designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum. Renew Inserts received 510(k)marketing clearance in 2012. It is estimated that Renew Inserts will benefit the 18 million people in the US suffering from ABL, a widespread yet silent condition.
Airflow Medical is developing a single-use device for the treatment of snoring and sleep apnea.
Sensate is developing a minimally-invasive device for the obesity market. This safe solution is fully reversible, and allows for gradual weight reduction using a novel mechanism of action.
Gard Medical is developing an single-use non-invasive device for the treatment of gastric reflux.
iWhisper is developing a discreet, lightweight, and wearable device that helps users lose weight and keep it off. The device uploads the information through a smartphone and provide coaching services. Completely noninvasive and easy to use, iWhisper represents a revolutionary and disruptive approach to the treatment of obesity, one of the largest unsolved medical problems today.
Osteogenix is a therapeutic products company that entered into a partnership with Medtronic to develop its lead compound for acceleration of fracture repair. In 2010, a wholly-owned subsidiary of Medtronic acquired substantially all of the assets of Osteogenix.
Neosil dermatology-focused specialty pharmaceutical company with several products in pre-clinical development and was subsequently sold to Peplin Pharmaceuticals. The company’s core topical anti-infective technology provides broad anti-microbial activity, long duration of activity, and excellent formulation flexibility.
Synteni pioneered the use of DNA microarrays for the genomic revolution. Starting with an academic research project, Shalon Ventures developed Synteni into one of the leading genomic players and service providers in four years. Two years after its founding, Shalon Ventures obtained follow-on funding for Synteni from Kleiner Perkins Caufield and Byers (www.kpcb.com), with Brook Byers joining the Synteni Board of Directors. Synteni was acquired in 1999 by Incyte (NASDAQ: INCY).
In collaboration with Sam Sawan PhD, a Professor of Chemistry at the University of Massachusetts, BioPolymerix developed a silver-based antimicrobial coating for medical applications. These proprietary coatings prevent infection and biofilm formation on a wide range of implantable medical devices. BioPolymerix was acquired by Biocompatibles International.